BioSante reports good results from phase II AML vaccine study


BioSante Pharmaceuticals is reporting positive results from a Phase II study investigating their GVAX Vaccine for acute myeloid leukemia. The company also learned that the FDA has granted GVAX Orphan Drug Status.

In the Phase II study, published in Blood, 85% of patients achieved a complete response to the therapy, which included the vaccine, immunotherapy-primed lymphocytes and an autologous stem cell transplantation.

BioSante is slowly building up a portfolio of cancer drugs: the company's GVAX Pancreas Vaccine was recently given Orphan Drug Status, and it currently has a 'vaccine' in clinical trials for breast cancer.

With few exceptions, true cancer vaccines have proven elusive for researchers, as they are unable to rouse a response from the immune system to attack the body's cancerous cells because those cells manage to escape detection.

By Ross Bonander

Source: BioSante

LymphomaInfo Social